Navigation Links
Omnitura Therapeutics Announces Private Placement Financing
Date:1/29/2009

Company will proceed with clinical trials of first-in-class multivalent therapies for cancer

REDWOOD SHORES, Calif., Jan. 29 /PRNewswire/ -- Omnitura Therapeutics Inc. ("Omnitura") announced today that it has entered into a $24 million private placement agreement with multiple closings. Under the terms of this financing, investments will be made in three tranches: $8 million before March 31, 2009, $8 million before December 31, 2009 and $8 million before December 31, 2010. "We anticipate that these funds will cover Omnitura's operations for three years and enable us to proceed with Phase I and Phase II clinical development of Aneustat(TM), our lead multivalent cancer therapy," said Jeff Dao, President & COO of Omnitura. "In addition to our clinical development program, these funds will also enable us to further cultivate strategic alliances and implement the next steps of our comprehensive financing plans," said Mr. Dao.

Aneustat(TM) represents a first-in-class multifunctional multitargeted (MFMT(TM)) therapy, specifically designed to address the heterogeneous nature of cancer. Omnitura has exclusive worldwide rights to Aneustat(TM) under a license agreement with Genyous Biomed International, Inc.

About Omnitura Therapeutics Inc. and MFMT(TM) Therapies

Omnitura Therapeutics Inc., www.omnitura.com founded in 2001, is a bio-pharmaceutical company that develops and facilitates the marketing of a new class of multivalent drugs for the treatment of cancer. Our mission is to commercialize Multifunctional Multitargeted ("MFMT(TM)") oncology drugs. MFMT(TM) drugs possess multiple therapeutic functions and act upon multiple biological targets to treat complex chronic diseases, including cancer.

Omnitura's MFMT(TM) drug candidates, acquired via an exclusive worldwide license and joint development arrangement with Genyous Biomed International Inc., were designed using a systems biology strategy that takes into consideration crosstalk between cancer cells, their microenvironment and the host organism (e.g. the immune system response). The comprehensive therapeutic activity profile of MFMT(TM) drugs represents an opportunity to significantly improve outcomes. By possessing multiple therapeutic functions and working through a multiplicity of biological targets, relatively low and well-tolerated doses of therapeutic actives are sufficient to treat cancer while minimizing disruption of and restoring the body's homeostasis. This unique characteristic of MFMT(TM) drug candidates leads to less risk of toxicity, side effects and the development of drug resistance.


'/>"/>
SOURCE Omnitura Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic" or the ... ("ILC") 2017 of the European Association for the Study of ... the positive effects of PBI-4050 on reduction of non-alcoholic steatohepatitis ... ... Gagnon, Vice-President of R&D Pre-clinical of Prometic "This extensive preclinical ...
(Date:4/20/2017)... and PETACH TIKVAH, Israel , April 20, ... developer of adult stem cell technologies for neurodegenerative diseases, announced ... present at the Alliance for Regenerative Medicine,s (ARM) 5 th ... April 27, 2017 at 09:40 EDT in Boston ... , MD, MHSc, Chief Medical Officer & Chief Operating Officer, ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... . The move comes after the company changed focus to making analytical tools ... brand and our new technology,” says CEO Robert Hart. Founders Bernardo Cordovez, Robert ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Global Opportunity Analysis and Industry Forecast, 2014-2022 ," the global market was valued ... 2022, registering a CAGR of 9.6% from 2016 to 2022. ... ...      ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... BROOKLYN, N.Y. , April 11, 2017 /PRNewswire-USNewswire/ ... identical fingerprints, but researchers at the New York ... University College of Engineering have found that partial ... fingerprint-based security systems used in mobile phones and ... previously thought. The vulnerability lies in ...
(Date:4/5/2017)... April 5, 2017  The Allen Institute for Cell ... Explorer: a one-of-a-kind portal and dynamic digital window into ... data, the first application of deep learning to create ... cell lines and a growing suite of powerful tools. ... these and future publicly available resources created and shared ...
Breaking Biology News(10 mins):